Find information on thousands of medical conditions and prescription drugs.

Teriparatide

Teriparatide (Forsteo®) is a recombinant form of parathyroid hormone, used in the treatment of advanced osteoporosis. more...

Home
Diseases
Medicines
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
Oxytetracycline
Phentermine
Tacrine
Tacrolimus
Tagamet
Talbutal
Talohexal
Talwin
Tambocor
Tamiflu
Tamoxifen
Tamsulosin
Tao
Tarka
Taurine
Taxol
Taxotere
Tazarotene
Tazobactam
Tazorac
Tegretol
Teicoplanin
Telmisartan
Temazepam
Temocillin
Temodar
Temodar
Temozolomide
Tenex
Teniposide
Tenoretic
Tenormin
Tenuate
Terazosin
Terbinafine
Terbutaline
Terconazole
Terfenadine
Teriparatide
Terlipressin
Tessalon
Testosterone
Tetrabenazine
Tetracaine
Tetracycline
Tetramethrin
Thalidomide
Theo-24
Theobid
Theochron
Theoclear
Theolair
Theophyl
Theophyl
Theostat 80
Theovent
Thiamine
Thiomersal
Thiopental sodium
Thioridazine
Thorazine
Thyroglobulin
Tiagabine
Tianeptine
Tiazac
Ticarcillin
Ticlopidine
Tikosyn
Tiletamine
Timolol
Timoptic
Tinidazole
Tioconazole
Tirapazamine
Tizanidine
TobraDex
Tobramycin
Tofranil
Tolazamide
Tolazoline
Tolbutamide
Tolcapone
Tolnaftate
Tolterodine
Tomoxetine
Topamax
Topicort
Topiramate
Tora
Toradol
Toremifene
Tracleer
Tramadol
Trandate
Tranexamic acid
Tranxene
Tranylcypromine
Trastuzumab
Trazodone
Trenbolone
Trental
Trest
Tretinoin
Triacetin
Triad
Triamcinolone
Triamcinolone hexacetonide
Triamterene
Triazolam
Triclabendazole
Triclosan
Tricor
Trifluoperazine
Trilafon
Trileptal
Trimetazidine
Trimethoprim
Trimipramine
Trimox
Triprolidine
Triptorelin
Tritec
Trizivir
Troglitazone
Tromantadine
Trovafloxacin
Tubocurarine chloride
Tussionex
Tylenol
Tyrosine
U
V
W
X
Y
Z

Administration

Teriparatide is administered by injection once a day in the thigh or abdomen. The recommended dose is 20 ╬╝g per day.

Uses

Teriparatide is a third-line agent in osteoporosis, after calcium/vitamin D supplementation and bisphosphonates. The bisphosphonates are effective in a large majority of osteoporosis patients, and only a minority would normally require teriparatide.

Mechanism of action

Teriparatide is the portion of human parathyroid hormone (PTH),amino acid sequence 1 through 34 of the complete molecule which contains amino acid sequence 1 to 84. Endogenous PTH is the primary regulator of calcium and phosphate metabolism in bone and kidney. Daily injections of teriparatide stimulate new bone formation leading to increased bone mineral density.

Teriparatide is the first FDA approved agent for the treatment of osteoporosis that stimulates new bone formation.

FDA approval

Forsteo was approved by the FDA on 26 November 2002, for the treatment of osteoporosis in postmenopausal women who are at high risk for having a fracture. The drug is also approved to increase bone mass in men with primary or hypogonadal osteoporosis who are at high risk for fracture.

Read more at Wikipedia.org


[List your site here Free!]


New anabolic agent may revamp osteoporsis Tx - Teriparatide Awaits FDA Approval
From OB/GYN News, 5/1/02 by Betsy Bates

HONOLULU -- The anticipated Food and Drug Administration approval of an anabolic agent, teriparatide, for the treatment of osteoporosis offers an intriguing opportunity to begin combining drugs or using them sequentially for enhanced effect, a number of speakers suggested at an international symposium sponsored by the National Osteoporosis Foundation.

Teriparatide, to be marketed by Eli Lilly & Co. as Forteo, is synthetic human parathyroid hormone 1-34 (PTH). Its mechanisms of action differ considerably from those of currently available antiresorptive agents, said Dr. Robert Neer, director of the osteoporosis center at Massachusetts General Hospital in Boston.

He reviewed his own and others' data about the bone-building potential of PTH, which reduces new vertebral fractures by 65% and nonvertebral fractures by more than 50% as it restructures the microarchitecture of the bone itself.

"Despite these impressive effects, bone mineral density is seldom restored to youthful levels. Fragility fractures, although reduced, are not eliminated," he said.

Combination therapy, therefore, might make sense to heighten results.

"PTH, like [insulin-like growth factor I] and growth hormone, increases bone resorption as well as bone formation. Therefore, combining PTH with an antiresorptive agent might possibly have a greater beneficial effect on bone mass and strength" than either agent alone, Dr. Neer said.

Three relatively small studies have explored the use of PTH in combination with hormone replacement therapy with mixed results. The first two found significant increases in spine and hip bone mineral density (BMD) with PTH, but no appreciably enhanced effect of adding HRT to the regimen. A 24-month study by E.B. Roe and associates, however, found an astounding 74% increase in vertebral trabecular BMD measured by quantitative computerized tomography and dual-energy x-ray absorptiometry--measured increases in spine, femoral neck, and total hip of 24%, 8%, and 10%, respectively.

Those results call for more study of the combination, Dr. Neer said.

Perhaps even more enticing are the conclusions of small studies of bisphosphonates or estrogens continued after discontinuation of PTH, Dr. John P. Bilezikian said at a satellite session sponsored by Eli Lilly & Co.

Dr. Bilezikian and his coinvestigators reported that a group of 14 men with osteoporosis who opted to start bisphosphonate therapy immediately upon stopping PTH continued to register increases in BMD over the next year, in contrast to 8 men who stopped all therapy and who "lost many of the gains" achieved during PTH therapy.

"These are very tentative conclusions ... but it would appear that after PTH, additional gains in BMD may be achieved with bisphosphonate therapy," said Dr. Bilezikian, chief of endocrinology and director of the metabolic bone diseases program at Columbia-Presbyterian Medical Center in New York.

Larger studies of combination and sequential therapy are planned, but in the meantime, Dr. Bilezikian said that he would feel comfortable prescribing short-term teriparatide (18-24 months) to patients with established osteoporosis to be followed by an antiresorptive medication.

In his separate presentation, Dr. Neer said that his own preference for now would be to treat patients at high risk for fractures with 2 years of teriparatide to be followed by an antiresorptive therapy.

COPYRIGHT 2002 International Medical News Group
COPYRIGHT 2002 Gale Group

Return to Teriparatide
Home Contact Resources Exchange Links ebay